Mortality and failure among tuberculosis patients who did not complete treatment in Vietnam: a cohort study

Vree, Marleen; Huong, Nguyen T.; Duong, Bui D.; Sy, Dinh N.; Le N Van; Co, Nguyen V.; Cobelens, Frank G. J.; Borgdorff, Martien W.
January 2007
BMC Public Health;2007, Vol. 7 Issue 1, p134
Academic Journal
Background: Tuberculosis treatment failure and death rates are low in the Western Pacific Region, including Vietnam. However, failure or death may also occur among patients who did not complete treatment, i.e. reported as default or transfer-out. We aimed to assess the proportion failures and deaths among new smear-positive pulmonary tuberculosis patients with reported default or transfer-out. Treatment outcomes rates were 1.4% default, 3.0% transfer-out, 0.4% failure and 2.6% death in northern Vietnam in 2003. Methods: Tuberculosis patients in 32 randomly selected district tuberculosis units in northern Vietnam were followed up 1 to 3 years after treatment initiation for survival, recent treatment history and bacteriologically confirmed tuberculosis. Results: Included were 85 transferred patients and 42 who defaulted. No information was available of 41 (32%), 28 (22%) had died. Fifty-eight were available for follow-up (46%); all had sputum smear results. Tuberculosis was recorded in 11 (13%), including 6 (7%) with positive sputum smears, 3 (3%) with negative smears but positive culture and 2 (2%) who had started re-treatment for bacteriologically confirmed tuberculosis. Fifteen (17%, 95%CI 10-27%) had died within 8 months after treatment initiation. Of 86 patients with known study outcomes, 39 (45%, 95%CI 35-56%) had died or had bacteriologically confirmed tuberculosis. This was recorded for 29/53 (55%, 95%CI 40-68%) transferred patients and 10/33 (30%, 95%CI 16-49%) patients who defaulted. Conclusion: The total failure and death rates are 0.6% and 0.8% higher than based on routine reporting in northern Vietnam. Although this was a large proportion of treatment failures and deaths, failure and death rates were low. Defaulting and transfer carry a high risk of failure and in particular death.


Related Articles

  • How does my doctor treat TB disease?  // Tuberculosis: Getting Healthy, Staying Healthy;Jun2008, Issue 8, p12 

    The article provides an answers to a question of how physicians treat tuberculosis (TB) disease.

  • Treatment outcome of extra-pulmonary tuberculosis in Finland: a cohort study. Vasankari, Tuula; Holmström, Pekka; Ollgren, Jukka; Liippo, Kari; Ruutu, Petri // BMC Public Health;2010, Vol. 10 Issue 1, p399 

    Background: We investigated the treatments given, the outcome and the patient- and treatment-system dependent factors affecting treatment outcome in a national two-year cohort of culture-verified extra-pulmonary tuberculosis cases in Finland. Methods: Medical records of all cases in 1995 -1996...

  • Poor adherence not enough to cause development of MDR-TB. Carter, Michael // CME: Continuing Medical Education;Nov/Dec2011, Vol. 29 Issue 11/12, p482 

    The article details a laboratory study published in the online edition of the "Journal of Infectious Diseases" which suggests that poor adherence is not enough to cause multidrug-resistent tuberculosis (MDR-TB). According to the study, failure of management of tuberculosis results from extremely...

  • A VERY SERIOUS NEW DISEASE - EXTENDED DRUGRESISTANT TUBERCULOSIS (XDR TB). Mitrea, Mirela; Birlutiu, Victoria; Deac, M. // Acta Medica Transilvanica;sep2011, Vol. 16 Issue 3, p329 

    Compared to germ sensitive tuberculosis (TB), in the case of multi-drug resistant (MDR TB) or extended drug-resistant tuberculosis (XDR TB) the prognosis is unfavourable, by prolonging therapy and its success is relatively limited. Early diagnosis and swift establishment of the target therapy...

  • Rifampin-associated tubulointersititial nephritis and Fanconi syndrome presenting as hypokalemic paralysis. Hong Ki Min; Oh Kim; Sang Ju Lee; Yoon Kyung Chang; Kwang Sun Suh; Chul Woo Yang; Suk Young Kim; Hyeon Seok Hwang // BMC Nephrology;2013, Vol. 14 Issue 1, p1 

    Background: Rifampin is one of the most important drugs in first-line therapies for tuberculosis. The renal toxicity of rifampin has been reported sporadically and acute tubulointerstitial nephritis (ATIN) is a frequent histological finding. We describe for the first time a case of ATIN and...

  • New TB Strategy. Stephenson, Joan // JAMA: Journal of the American Medical Association;3/16/2005, Vol. 293 Issue 11, p1316 

    Reports on research from Korea which suggests that combining standard TB drug therapy with a vaccine containing M tuberculosis DNA might offer a cure. Experiments with mice with standard drugs or the combination in which reactivated infections were seen in 6 to 10 mice on standard therapy...

  • Tuberculosis in an Urban Area in China: Differences between Urban Migrants and Local Residents. Xin Shen; Zhen Xia; Xiangqun Li; Jie Wu; Lili Wang; Jing Li; Yuan Jiang; Juntao Guo; Jing Chen; Jianjun Hong; Zheng'an Yuan; Qichao Pan; DeRiemer, Kathryn; Guomei Sun; Qian Gao; Jian Mei // PLoS ONE;Nov2012, Vol. 7 Issue 11, Special section p1 

    Background: The increase in urban migrants is one of major challenges for tuberculosis control in China. The different characteristics of tuberculosis cases between urban migrants and local residents in China have not been investigated before. Methodology/Principal Findings: We performed a...

  • ATS, CDC, and IDSA Update Recommendations on the Treatment of Tuberculosis. Neff, Matthew // American Family Physician;11/1/2003, Vol. 68 Issue 9, p1854 

    Focuses on the joint statement of recommendations published by the American Thoracic Society, the U.S. Centers for Disease Control and Prevention and the Infectious Diseases Society of America in June 2003 for the treatment of tuberculosis. Goals for treatment of tuberculosis; Recommended...

  • Treatment of Tuberculosis: Use of Active Pharmaceuticals. Samad, Abdus; Sultana, Yasmin; Akhter, S.; Aqil, Mohammad // Recent Patents on Anti-Infective Drug Discovery;Jan2008, Vol. 3 Issue 1, p34 

    Tuberculosis (TB) is a highly infectious disease caused by several species of mycobacteria. Multi drug resistant strains of mycobacteria leading to the increase of patient world wide. There is an urgent need for new effective antimicrobial agent to replace those currently in use because of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics